CHANDLER, Ariz.–(BUSINESS WIRE)–Nationwide Vision is celebrating its 40th anniversary of delivering high-quality eye care to Arizona communities.
Category: Business
Nationwide Vision Celebrates 40 Years of Serving Arizona’s Eye Care Needs
CHANDLER, Ariz.–(BUSINESS WIRE)–Nationwide Vision is celebrating its 40th anniversary of delivering high-quality eye care to Arizona communities.
Pair Eyewear Implements Veero® EyeSize Fit-Optimization Software to Deliver Precision Fit to Online Shoppers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Veero, the SaaS platform solving online eyewear fit, today announced Pair Eyewear, the direct-to-consumer brand reimagining glasses as a form of self expression, has launched Veero’s EyeSize solution. The relationship…
Sightview Appoints Jeff Macomber as Chief Technology Officer
DURHAM, N.C.–(BUSINESS WIRE)– #EHR–As chief technology officer, Jeff Macomber will modernize and unify Sightview’s offerings for optometrists, ophthalmologists and opticians.
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the t…
jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). …
Saudi Arabia OTC Artificial Tears Market Report 2025-2033 | Vision 2030 Boosts Retail and Online Channels, Non-Prescription Eye Care Boom Fuels Expansion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Saudi Arabia OTC Artificial Tears Market – Demand & Forecast 2025-2033” report has been added to ResearchAndMarkets.com’s offering. Saudi Arabia OTC Artificial Tears Market is expected to reach US$ 79.09 million by 203…
Bausch + Lomb to Participate in Upcoming Investor Conferences
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two invest…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
First FDA-Approved Treatment for MacTel Performed
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the first commercial manufacturing, shipment, and surgical procedure for EN…
Warby Parker Announces Second Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. “It has been a bu…
STAAR Surgical Reports Second Quarter 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June…
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that To…
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business …
National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision,” “we,” “our,” “us” or the “Company”) today reported its financial results for the second quarter ended June 28, 2025. “Our strong performance this quarter ref…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company will participate in…
Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase I…
iCare World USA Appoints Dawna Owens as Director of Strategic Partnerships
RALEIGH, N. C.–(BUSINESS WIRE)– #Ophthalmology–Dawna Owens joins iCare USA as Director of Strategic Partnerships, strengthening alliances across healthcare and enterprise sectors.
Glaukos Announces Second Quarter 2025 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…